text size  A   A

Nutritional Support for People with Moderate to Advanced AMD*

PreserVision Eye Vitamin AREDS 2 Formula Soft Gels

preservision-eye-vitamins-areds-2

Many AMD sufferers are taking a separate fish oil supplement with Omega-3 fatty acids in addition to the PreserVision Eye Vitamin AREDS Formula. PreserVision Eye Vitamin AREDS 2 Formula includes 1,000 mg omega-3 fatty acids, so that patients may not need to purchase a separate fish oil supplement or take extra fish oil pills.

Available in 4 per day Soft Gels.

PreserVision Eye Vitamin AREDS 2 Formula is based on the original Bausch + Lomb PreserVision Eye Vitamin AREDS Formula, and is a high potency antioxidant supplement with select vitamins and minerals, at levels well above those in ordinary multivitamins and generally not attainable through diet alone*.1-3

Key Features & Benefits

  • Bausch + Lomb PreserVision Eye Vitamin AREDS 2 Formula is based on the original PreserVision Eye Vitamin AREDS Formula - the #1 Recommended eye vitamin and mineral supplement among vitreoretinal eye doctors*.1-2,4
  • Based on the latest research in eye vitamin supplementation.5-7
  • More than 100% of the U.S. Daily Values for Vitamins C and E.
  • High levels of omega-3 fatty acids, lutein and zinc (zinc oxide).

Ingredients

PreserVision 2 Eye Vitamins Supplement Facts

Directions

Take 4 Soft Gels per day, 2 in the morning, 2 in the evening with a full glass of water and during a meal.

*The statements above have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

**Professional Samples are for eye care practitioners only. A qualified practitioner, for this program, is defined as one that is on a registered list compiled through the American Medical Association. Good only in USA. Samples are not for resale. Any other use constitutes fraud.

PreserVision is a registered trademark of Bausch & Lomb Incorporated. AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS). AREDS2® is an ongoing study that is expected to end in 2013.

1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119(10):1417–1436.
2. PreserVision Eye Vitamin AREDS Soft Gel formula. Bausch + Lomb Web site. Accessed January 7, 2010.
3. PreserVision AREDS 2 Eye Vitamin and Mineral Supplement Label. Bausch + Lomb Incorporated.
4. March 2009 Retinal AMD Tracker, Decision Analysts, Inc. 
5. Clinical studies database: Age-Related Eye Disease Study 2 (AREDS2). National Eye Institute Web site. http://www.nei.nih.gov/neitrials/viewStudyWeb. aspx?id=120. Accessed October 16, 2009.
6. Age-Related Eye Disease Study 2: Manual of Procedures. The EMMES Corporation Web site. https://web.emmes.com/study/areds2/resources/areds2_ mop.pdf. Accessed January 8, 2010.
7. Bausch & Lomb Incorporated. PreserVision AREDS 2 Eye Vitamin and Mineral Supplement Label.
8. Augood C, Chakravarthy U, Young I, et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr. 2008;88(2):398–406.
9. SanGiovanni JP, Chew EY, Clemons TE, et al; for Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007;125(9):1225–1232.
10. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol. 2006;124(7):981–986.
11. Tan JSL, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration. The Blue Mountains Eye Study. Ophthalmology. 2008;115(2):334–341.
12. Bressler NM. Age-related macular degeneration is the leading cause of blindness: [Commentary by Neil M. Bressler, MD]. JAMA. 2004;291(15):1900–1901.
13. Friedman DS, O’Colmain BJ, Muñoz B, et al; for The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572.